Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.61 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139996 | 1.00 | TRPV4 (0.61) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL5430612 | 0.96 | TRPV4 (0.59) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL5441760 | 0.96 | TRPV4 (0.59) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL4127966 | 0.91 | TRPV4 (0.62) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL4149235 | 0.90 | TRPV4 (0.61) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL5434508 | 0.90 | TRPV4 (0.59) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL14361010 | 0.90 | TRPV4 (0.59) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL13872387 | 0.89 | TRPV4 (0.61) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL5447917 | 0.89 | TRPV4 (0.61) | TRPV4BMP1TAS1R3TAS1R1CTSB | |
| SCHEMBL14361121 | 0.89 | TRPV4 (0.61) | TRPV4BMP1TAS1R3TAS1R1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885BMP1 2172/4885TAS1R3 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.